Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.61 |
| ▸ | KMO | O15229 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528069 | 0.88 | AKR1C3 (0.55) | AKR1C3AKR1C2KMOEPHX2PDK2 | |
| SCHEMBL29630556 | 0.87 | ALDH1A1 (0.51) | AKR1C3AKR1C2KMOEPHX2SCN9A | |
| SCHEMBL2832477 | 0.86 | SCN9A (0.58) | AKR1C3AKR1C2PDK2SCN9A | |
| SCHEMBL7067814 | 0.86 | SCN9A (0.50) | AKR1C3AKR1C2EPHX2SCN9A | |
| SCHEMBL423796 | 0.86 | AKR1C3 (0.62) | AKR1C3AKR1C2PDK2SCN9A | |
| SCHEMBL28498920 | 0.85 | AKR1C3 (0.47) | AKR1C3AKR1C2EPHX2SCN9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL29833674 | 0.84 | SCN9A (0.57) | AKR1C3AKR1C2PDK2SCN9A | |
| SCHEMBL28371576 | 0.84 | RXRA (0.58) | AKR1C3AKR1C2KMOPDK2PTGER1 | |
| SCHEMBL4789279 | 0.83 | AKR1C3 (0.48) | AKR1C3AKR1C2EPHX2SCN9A | |
| SCHEMBL14038653 | 0.83 | SCN9A (0.48) | AKR1C3AKR1C2SCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101820950-A | Biphenylcarboxamide derivatives as hedgehog pathway modulators | IRM LLC | 2010-09-01 | — | — | CN | claimed |
| CN-101218201-A | Benzoic acid derivatives as GlyR modulators or agonists | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | CN | claimed |
| JP-2007519744-A | — | — | 2007-07-19 | — | — | JP | claimed |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | claimed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | claimed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | claimed |
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| CN-101820950-B | Biphenylcarboxamide derivatives as hedgehog pathway modulators | IRM LLC | 2015-01-21 | — | — | CN | disclosed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | disclosed |
| CN-102170873-B | Smoothied antagonism for treating disorders associated with HEDGEHOG pathways | NOVARTIS AG | 2014-07-30 | — | — | CN | disclosed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2004-10-28 | — | — | US | disclosed |
| EP-0699185-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
| EP-0699185-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | AKR1C3 386/4885AKR1C2 508/4885KMO 1043/4885 |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | CTSV, CTSB, CTSS | AKR1C3 1571/4885AKR1C2 2025/4885KMO 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.